SLU-PP-332: What It Is, How It Works and What We Know So Far
SLU-PP-332 has been called “exercise in a bottle” by just about every outlet that’s covered it. The compound earned that label from animal studies showing increased fat burning, longer endurance, and improved body composition, all without the animals moving more or eating less.
The results are genuinely interesting, though everything published so far comes from mice, not people. This is what the research supports, where the gaps are, and how our providers evaluate SLU-PP-332 for patients who ask about it.
What Is SLU-PP-332?
SLU-PP-332 is a lab-made compound that mimics the metabolic effects of aerobic exercise. In animal studies, mice treated with it burned more fat, ran longer, and produced energy more efficiently at the cellular level. It has not completed human clinical trials and is not FDA-approved.
It works by activating estrogen-related receptors (ERRs), which, despite the name, have nothing to do with estrogen. These receptors control how your cells produce energy and metabolize fat. SLU-PP-332 binds to all three subtypes, most strongly to ERRα.
Researchers at Saint Louis University developed the compound in the lab of Dr. Thomas Burris (the “SLU-PP” is just the university abbreviation plus a lab code). The press calls it “exercise in a bottle,” which works as headline shorthand but overpromises what a single compound can deliver. Our team uses SLU-PP-332 within a personalized protocol when the labs and goals support it, and we treat that label with the skepticism it deserves.
How SLU-PP-332 Works
SLU-PP-332 activates the same genes that aerobic exercise turns on. It binds to estrogen-related receptors (ERRs) inside your cells, which tells the cell to build more mitochondria, burn more fat for fuel, and shift muscle fibers toward the slow-twitch, endurance-favoring type.
In mice, a single dose changed the fuel mix within two hours. The animals shifted from burning mostly carbohydrates to burning mostly fat (the same shift that happens during a long run). Over 28 days of dosing, fat oxidation increased by roughly 25% compared with untreated animals.
It is not a stimulant and it does not suppress appetite. The mechanism is cellular: the compound signals your body to behave as though it just finished a training session, even at rest.
What has SLU-PP-332 done in studies?
Every result listed here comes from preclinical research in mice. No human efficacy data exists yet.
In published animal studies, SLU-PP-332 has:
- Increased fat burning and reduced fat mass without any change in food intake
- Extended treadmill running time by 70% and distance by 45%¹
- Improved blood sugar control in obese mouse models
- Improved heart function and reduced scar tissue in mice with induced heart failure²
- Reduced inflammation and restored cellular energy production in aging kidney tissue³
- Shifted muscle fibers toward the slow-twitch, endurance-favoring type
The weight loss data gets the most attention. Obese mice treated with the compound gained roughly ten times less fat than untreated controls and lost about 12% of their body weight, while eating and moving the same amount as untreated animals.⁴
Semaglutide and tirzepatide produce 12 to 18% body weight reduction in human trials by suppressing appetite. SLU-PP-332 works the other side of the equation: energy output, not intake. Different mechanisms, and a very different depth of human evidence behind them. If GLP-1 medications are already part of your conversation, our medical weight loss programs cover the appetite side under provider supervision.
Is SLU-PP-332 Safe?
No human clinical trial has been completed as of May 2026. ClinicalTrials.gov does not list a published phase 1 study. Everything known about safety comes from animal data and anecdotal use.
In the metabolic syndrome study,⁴ mice dosed for up to 28 days showed no liver, kidney, or cardiac toxicity. The compound did not suppress appetite or act as a stimulant, and researchers noted no severe adverse effects at the doses tested. The heart failure² and aging kidney³ studies both found protective effects rather than organ damage.
Side effects reported in non-clinical use (anecdotal, not from controlled trials):
- A brief rise in body temperature for roughly 30 minutes after injection
- Increased sweating, particularly during physical activity
Long-term human safety is unknown. Effects on fertility, cancer risk, cardiac remodeling, and chronic metabolic adaptation have not been studied in people. This is why our board-certified providers require a full hormone panel, comprehensive lab work, and a clear clinical reason before including SLU-PP-332 in any protocol.
Is SLU-PP-332 FDA-approved?
SLU-PP-332 is not FDA-approved and is not a controlled substance. It is classified as a research compound, and most vendors sell it labeled “for research purposes only.” No completed human clinical trial exists as of May 2026.
Researchers at Saint Louis University have developed a successor compound called SLU-PP-915 with improved oral bioavailability, which signals continued interest in moving this class of compounds toward the clinic. Neither compound has entered human trials yet.
The compound is sold through online research chemical vendors, not through licensed compounding pharmacies. Sourcing quality varies, and most consumer-facing sales sit in a regulatory gray area. Using SLU-PP-332 without lab work, provider oversight, and verified sourcing is where real risk shows up.
This is the part our team takes most seriously. SLU-PP-332 only enters a Dynamis protocol through licensed, pharmaceutical-grade sourcing, never from an unverified online vendor.
Should you consider SLU-PP-332?
SLU-PP-332 is one of the more interesting compounds to come out of metabolic research in recent years, and the early data on fat oxidation, endurance, and body composition has our providers paying close attention. The question isn’t whether the science is promising. It’s whether it fits your labs, your goals, and your current protocol.
That’s what our Kickoff Call is built for. A short conversation with our team to figure out whether SLU-PP-332, or a different approach entirely, is the right move for where you are right now. Once you’re on protocol, a dedicated Personal Health Coach stays with you for questions, check-ins, and the day-to-day of staying on track.
Book Your Kickoff Call
Studies cited
1. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity — Journal of Pharmacology and Experimental Therapeutics, 2024
2. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function — Circulation, 2024
3. Estrogen-related receptor agonism reverses mitochondrial dysfunction and inflammation in the aging kidney — The American Journal of Pathology, 2023
4. A synthetic ERR agonist alleviates metabolic syndrome — Journal of Pharmacology and Experimental Therapeutics, 2024
